cyrilzakka/clinical-trials huggingface dataset:
The Role of Cerebral Hemodynamics in Moyamoya Disease

The purpose of this study is to determine if people with moyamoya disease who have insufficient blood flow are at a higher risk for stroke.

Moyamoya disease is a rare medical disorder that affects the blood vessels (pipes that transport blood) in the brain. In Moyamoya disease, the large blood vessels in the middle of the brain close down over time. The cause of this disorder is unknown. In order to compensate for this narrowing, the body grows new small blood vessels around the blockage. These small branches grow larger (and may be more numerous) to give the disorder its name. "Moyamoya" is the Japanese term for "puff of smoke" and is used to describe the hazy appearance of these small blood vessels on an angiogram.

Treatment for moyamoya is difficult because so little is known about the disease. Some people never have a stroke while others may have several. It is likely that the strokes are due to insufficient blood flow to the brain. There are surgical procedures that may improve blood flow to the brain, however, these procedures may cause complications and may not always improve the blood flow.

The main purpose of this study is to determine if people with moyamoya disease who have insufficient blood flow are at a higher risk for stroke. In this study researchers will learn more about the risks and potential benefits of surgical treatment. This information will help decide if there are people at higher risk for stroke who might benefit from surgery or if there are those at a lower risk who might not benefit.

In this study, participants will undergo baseline clinical and laboratory evaluation. Measurements of blood flow to the brain and oxygen use will be obtained using by positron emission tomography (PET). Participants will be followed for up to 5 years. PET studies will be conducted one and three years after enrollment to determine if blood flow improves over time. Participants treated with surgery (at the discretion of their treating physicians) will also be followed for perioperative complications, improvement in blood flow, and long term risk of stroke.

Eligibility Criteria:
Inclusion Criteria:

* Adult \> 18 years of age
* Capable of informed consent
* Clinical: Both asymptomatic and symptomatic patients will be included.
* Anatomic: Unilateral or bilateral imaging findings consistent with moyamoya collaterals (Suzuki stages 3 and 4) on digital subtraction, computed tomographic, or magnetic resonance angiography (after Suzuki and Kodama, 1983)

Exclusion Criteria:

* Any other disease that might be responsible for the vasculopathy, including atherosclerosis, neurofibromatosis, meningitis, sickle cell disease, skull base radiation therapy.
* Pregnancy: All women of child-bearing potential will be tested for pregnancy on the day of the enrollment and throughout the course of the study.
* Surgery: Prior open or endovascular revascularization procedures, unless there have been ischemic symptoms since surgery and angiographic evidence that the procedure was not successful
Compare Swallowing Kinematics and Suprahyoid Muscle Activation Among Three Different Swallowing Tasks

The aim of this study is to swallowing kinematics and suprahyoid muscle activation among Masako, Mendelsohn Maneuvers and new-designed Mouth Open Swallowing Maneuver

Swallowing disorder can result in aspiration pneumonia, dehydration, malnutrition and even death. Therefore, it is a condition that needs to be detected, prevented and/or treated at an early stage. In the rehabilitation process of swallowing disorders, many exercise approaches are used, as well as compensatory postures and maneuvers. In addition to creating compensation and increasing swallowing muscle strength, the maneuvers used also change the temporal parameters associated with swallowing, such as delay in the swallowing reflex and time to close the airway.

Mendelson maneuver and Masako maneuver are the most commonly used swallowing maneuvers in swallowing rehabilitation. During the Mendelson maneuver, the patient is asked to voluntarily hold larynx when larynx is elevated. Masako maneuver is swallowing with tongue positioned between anterior teeth. Mouth Open Swallowing Maneuver is new-designed exercise. 10 mm wedge is comfortably positioned on the molar teeth and patient is asked to swallow in this way. We think that the explosive force that occurs more hyolaryngeal displacement than normal swallowing. Therefore, The targets of all three exercises in the swallowing physiology is different. It is important to investigate the effects of all three exercises on swallowing physiology in order to determine a patient-specific rehabilitation program and develop new techniques.

Eligibility Criteria:
Inclusion Criteria:

* Volunteering to participate in the study,
* Getting less than 3 points from the T-EAT-10 (Turkish Eating Evaluation Questionnaire) questionnaire

Exclusion Criteria:

* Having disc herniation, mechanical neck pain or any pathology in the cervical region.
* Having a temporamandibular joint problem that may affect joint biomechanics and muscle functions.
* Having any neurological or systemic disease,
* Having undergone head and neck surgery or received radiotherapy.
Evaluation of a Support Software in the Planning and Real-time Monitoring of the Insertion of Needles in Interventional Magnetic Resonance Imaging (MRI): Liver Biopsy Case

To demonstrate that the use of Standard @IFE and Planning@IFE features of the IFE software, compared to the current method, when planning and inserting the needle under MRI monitoring in the context of liver biopsies enable:

* a facilitation of the planning stages of the procedure (route path, marking of the entry point and alignment of the MRI cutaways on the planned path), resulting in a reduction in the duration of the planning stages,
* a facilitation of the real-time modification of MRI cutaways during the procedure, resulting in a reduction of the duration of the procedure


Eligibility Criteria:
Inclusion Criteria:

* Patient is at least 18 years old
* Affiliated to a social security scheme
* Informed consent
* Patient with an indication of liver biopsy eligible for a biopsy under interventional MRI

Exclusion Criteria:

* Patient with a contraindication for MRI exam
* Patient with a contraindication for performing a biopsy
* Pregnancy
* Exclusion period
* Patient unable to receive and understand information about the study
* Patients under guardianship
* Patients under judicial protection
Safety and Feasibility of Pulmonary Surgery Marker System in the Intraoperative Localization of Small Pulmonary Nodules

As the detection of small pulmonary nodules continuously grows, the intraoperative localization of small pulmonary nodules is in great demand. The intraoperative localization nowadays is usually done under local anesthesia before surgery. There is a certain rate of failure and complication. The result of our early animal experiments show that the pulmonary surgery marker system can deliver the intraoperative localization safely and precisely under anesthesia, and the average distance between the localization and the simulated lesion is less than 5mm during surgery. Therefore, the safety and feasibility of the system require further evaluation in patients

This is a prospective, single-center clinical trial initiated by the investigator. LungBrella marker can be accurately implanted into a predetermined position in the lung assisted by JediVision software and successfully marked the pulmonary nodules which needs to undergo Video-assisted thoracoscopic surgery. The study is expected to enroll 10 patients. Finally, the effectiveness and safety of the method will be evaluated. This method not only can complete pulmonary nodule localization in the operating room without occupying the resources of radiology department, but also can let patients receive pulmonary nodule location after anesthesia. Thereby the risks during transportation are avoided and the suffering of patients is reduced.

Eligibility Criteria:
Inclusion Criteria:

Subjects should meet all of the following criteria

* diagnosis of pulmonary nodule, single nodule operation to be performed and nodule to be located by the decision of chief surgeon.
* commit to follow the research procedures and cooperate with the implementation of the whole process research
* 1 / 3 of pulmonary nodules are located in the periphery of the lung
* signed informed consent with date

Exclusion Criteria:

* the target lesion is close to the hilar or large blood vessels
* subjects with FEV1 less than 1.2 in lung function
* subjects with cardiac function III and cardiac function IV (NYHA, New York)
* subjects with uncontrollable acute pleura infection
* patients with previous history of thoracic surgery (thoracotomy), plural infection, and plural thickening and adhesion on the affected side
* Other factors that investigators disagree enrollment.
Evaluating the Efficacy of PKU Synergy in Patients Expressing Phenylketonuria or Hyperphenylalaninemia

This study centres around a new one-a-day phenylalanine-free protein substitute for phenylketonuria patients. Fifty eligible adults (≥ 16 years) with proven phenylketonuria or hyperphenylalaninemia will be recruited and randomly allocated to one of two intervention arms (n = 25 per arm). Following a 3-day baseline period, and in addition to routine nutritional management, patients will receive either one sachet of the new protein substitute daily (intervention) or continue their usual dietary and/or protein substitute regimen (maximum of 1 protein substitute per day (equal to 20g protein equivalent) control) for 28 days.

This study centres around a new one-a-day phenylalanine-free protein substitute for phenylketonuria patients. In particular, this randomised controlled trial aims to evaluate the efficacy (changes relating to nutritional status and metabolic control) of this new protein substitute, while also capturing data pertaining to tolerance, compliance, safety and acceptability. Designed for poorly compliant adult patients with proven phenylketonuria or hyperphenylalaninemia, this new protein substitute is composed of an adapted mixture of other essential and non-essential amino acids, carbohydrates, vitamins and selected minerals and trace elements and enriched with docosahexaenoic acid (DHA). Fifty eligible adults (≥ 16 years) will be recruited and randomly allocated to one of two intervention arms (n = 25 per arm). Following a 3-day baseline period, and in addition to routine nutritional management, patients will receive either one sachet of the new protein substitute daily (intervention) or continue their usual dietary and/or protein substitute regimen (maximum of 1 protein substitute per day (equal to 20g protein equivalent) control) for 28 days.

Eligibility Criteria:
Inclusion Criteria:

* Male or female
* Over 16 years of age
* Diagnosed with proven PKU or hyperphenylalaninemia with an increased phenylalanine-tolerance/intake
* Currently taking a maximum of 1 protein substitute per day (equal to 20g protein equivalent)
* Have a minimum blood phenylalanine level of ≥ 600 umol/L (for PKU patients)
* Have relaxed (if not stopped) their dietary and protein substitute regimen for at least 1 month prior to trial commencement
* Have Written informed consent from patient

Exclusion Criteria:

* Pregnant or lactating
* Requiring nutritional support (including enteral and parenteral nutrition)
* Major hepatic or renal dysfunction
* Participation in other studies within 1 month prior to entry of this study
* Allergy to any of the study product ingredients, including milk protein or soya
* Investigator concern around willingness/ability of patient to comply with protocol requirements
Kinesiophobia and Pressure Sore Risk After Bariatric Surgery.

The aim of this study was to investigate the effect of emotional freedom technique on kinesiophobia and the risk of developing pressure sores in patients undergoing obesity surgery.

The hypotheses of the study are as follows:

H1-0: Emotional liberation technique has no effect on kinesiophobia in patients undergoing bariatric surgery.

H1-1: Emotional liberation technique has a positive effect on kinesiophobia in patients undergoing bariatric surgery.

H2-0: Emotional liberation technique has no effect on the risk of developing pressure ulcers in patients undergoing bariatric surgery.

H2-1: Emotional liberation technique has a positive effect on the risk of developing pressure ulcers in patients undergoing bariatric surgery.

Intervention Group: After the pre-test application (Personal Introduction Form, Tampa Kinesiophobia Scale and Braden Pressure Sore Risk Assessment Scale) EFT was applied to the patients when they were stable before the bariatric surgery and they were taught to do it on their own. After the bariatric surgery, the patients were asked to do 1 session of EFT and were accompanied. After the application, the patients were applied post-tests (Tampa Kinesiophobia Scale and Braden Pressure Sore Risk Assessment Scale). EFT training was given by a researcher who has a certificate in the field.

Control Group Patients were administered pre-tests (Personal Introduction Form, Tampa Kinesiophobia Scale and Braden Pressure Sore Risk Assessment Scale) at a stable time before bariatric surgery. Post-tests (Tampa Kinesiophobia Scale and Braden Pressure Sore Risk Assessment Scale) were administered to patients after bariatric surgery at a stable time. After the post-tests, EFT was administered to patients in the control group.

Eligibility Criteria:
Inclusion Criteria:

1. Being 18 years of age or older
2. Having had obesity surgery
3. Not having any visual or auditory problems
4. Not having any psychiatric problems.

Exclusion Criteria:

1. Not accepting to participate in the study or wanting to leave
2. Being under 18 years of age.
The Importance of Inflammatory Markers Calculated From Preoperative and Postoperative Peripheral Blood Results in the Diagnosis and Treatment of Patients Operated for Hydatid Cyst of the Lung (Lung Echinococcus Granulosus)

This study aims to investigate the role of these laboratory findings in the differential diagnosis and management of pulmonary hydatid cyst (PHC) by examining the number of euzonophils, neutrophils, lymphocytes, platelets and neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and systemic immune inflammatory index values in the peripheral blood of patients diagnosed with pulmonary hydatid cyst (PHC) in the preoperative period and post-operative 3rd month. Although we have extensive data on hydatid liver cysts, there is limited information in the literature on the laboratory values of patients with PHC. This study aims to provide more scientific basis for the diagnosis and management of PHC and is considered as an inexpensive, reproducible and easily calculable method to improve the accurate diagnosis and management of AKH in clinical practice.

Hydatid cyst of the lung (HCC) is a health problem caused by a small species of tapeworm called Echinococcus granulosus, a parasitic infection that can occur in humans and other mammals. Hydatid cysts are cysts caused by the larvae of the parasite. They most commonly form in the liver and lungs, but can also occur in other organs. E. granulosus lives in the intestines of animals and excretes them in their feces. Humans can get the eggs of this parasite through contact or under poor hygiene conditions. The ingested eggs hatch in the stomach and intestine and the larvae enter the bloodstream, then form cysts in various organs throughout the body.

Cystic echinococcosis is a disease in which a large group of patients live in conditions of material and social poverty. The disease has a widespread distribution worldwide and the regions with high disease prevalence are Southeast Europe, the Middle East, North, Central and East Asia and South America.

Eligibility Criteria:
Inclusion Criteria:

* Between January 1, 2022 - December 1, 2023, patients with hydatid cyst of the lung who were hospitalized in the Thoracic Surgery Service

Exclusion Criteria:

* Between January 1, 2022 and December 1, 2023, other patients admitted to the Thoracic Surgery Service
The Effect of Neuroathletic Training in Cross-country Skiers

The aim of this study was to investigate the effects of neuro-athletic training on physical performance and position sense in cross-country skiers.

Cross-country skiing is the least dangerous but tiring winter sport performed in snowy environments with different heights, distances, and slopes using ski equipment such as skis, shoes, and poles with various features. In this sport, both the lower and upper body require rapid power production and high maximal oxygen consumption. When technique, conditioning, and skill are combined in cross-country skiing, the resulting performance reaches the highest level. In order for an athlete to perform well, they must have the capacity to produce power continuously and quickly. Cross-country skiing is often associated with the development of strength, speed, agility, balance, endurance, fatigue resistance, and oxygen capacity. Physical training alone is not enough for an athlete to achieve high success. Physical training must be combined with the visual system, vestibular system, and proprioceptive system. The quality of the stimuli coming from these systems in an athlete positively affects the athlete's physical performance and success in competitions. Therefore, in addition to the physical training that the athlete will do, neuro-athletic training that stimulates the visual, vestibular, and proprioceptive systems will be implemented in the cross-country skiing sports branch, considering that it can increase the athlete's performance by improving muscle strength, core endurance, balance, and proprioceptive sense. The sample of the study will consist of 26 cross-country skiing athletes between the ages of 12-18 who participate in training at the Arkut Cross-Country and Biathlon Center. The athletes will be randomly divided into 2 groups by coin toss method. All athletes will participate in routine training. Neuroathletic training will be given to one group in addition to routine training, and its effect on the athletes' performance will be examined.

Eligibility Criteria:
Inclusion Criteria:

* Have been cross-country skiing for at least 3 years and regularly participate in training
* Be a volunteer
* Complete a Trail Making Test

Exclusion Criteria:

* Have had lower extremity surgery in the last 2 years
* Have no neurological or orthopedic disorders
Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer

The purpose of this study is to investigate whether endostar (recombinant human endostatin)with cisplatin and capecitabine (Xeloda) as 1st line treatment in the advanced gastric cancer is effective and safe.

Endostar, a recombinant human endostatin, has shown its antitumor ability in combination in NSCLC and breast cancer. But to gastric cancer, few clinical data has been reported. However, bevacizumab, an angiogenesis inhibitor was shown effective in combination with chemotherapy in advanced gastric cancer in some phase II study. So in this study, we want to explore whether endostar is also effective and safe in advanced gastric cancer. Response predictive factor is expected to be identified.

Eligibility Criteria:
Inclusion Criteria:

* Having signed informed consent
* Age 18 to 70 years old
* Histologically confirmed gastric adenocarcinoma
* Unresectable recurrent or metastatic disease
* Previous neo-adjuvant or adjuvant treatment for gastric cancer, if applicable, more than 6 months
* Previous chemotherapy with capecitabine or cisplatin, if applicable, more than 12 months.
* Measurable disease according to the RECIST criteria
* Karnofsky performance status ≥60
* Life expectancy of ≥2 month
* No prior radiotherapy except radiotherapy at non-target lesion of the study more than 4 weeks
* ALT and AST\<2.5 times ULN (≤5 times ULN in patients with liver metastases)
* Serum albumin level ≥3.0g/dL
* Serum AKP \< 2.5 times ULN
* Serum creatinine \<ULN, and CCr \< 60ml/min
* Bilirubin level \< 1.5 ULN
* WBC\>3,000/mm3, absolute neutrophil count ≥2000/mm3, platelet\>100,000/mm3, Hb\>9g/dl

Exclusion Criteria:

* Brain metastasis (known or suspected)
* Previous systemic therapy for metastatic gastric cancer
* Inability to take oral medication
* Previous therapy targeting at angiogenesis or vasculogenesis pathway or other targeted therapy
* Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry
* Contraindications of nuclear magnetic resonance image such as fitment of cardiac pacemaker , nerve stimulator, or aneurysm clip, and metallic foreign body in eye ball and so on.
* Allergic constitution or allergic history to protium biologic product or any investigating agents.
* Severe heart disease or such history as recorded congestive heart failure, uncontrolled cardiac arrhythmia, angina pectoris needing medication, cardiac valve disease, severe abnormal ECG findings, cardiac infarction , or retractable hypertension.
* Pregnancy or lactation period
* Any investigational agent within the past 28 days
* Other previous malignancy within 5 year, except non-melanoma skin cancer
* Previous adjuvant therapy with capecitabine+platinum,
* Pre-existing neuropathy\>grade 1
* Legal incapacity
A 8-month Study on the Use of Intra-oral Camera and Text Messages on Gingivitis Control

To investigate the effects of using an intra-oral camera (IOC) during supportive periodontal therapy, and oral hygiene mobile text messages (SMS) between appointments on clinical, behavioral and psychological parameters of patients with gingivitis.

Dental hygiene behaviours are of paramount importance for controlling gingival health. There is evidence on the use of IOC and of text messages in boosting motivation, sustainability and clinical efficacy of dental hygiene behaviors. Orchestrating these two technologies is expected to create a coaction effect which could improve behavior change interventions, but the effectiveness of such strategy needs to be inspected.

Eligibility Criteria:
Inclusion Criteria:

Gingivitis BOMP \> 0.5 20 teeth (minimum 5 per quadrant) \> 18 years old

Exclusion Criteria:

periodontitis (pockets \>3), smoking, orthodontics, pregnancy removable partial dentures
Modulation of Visually Evoked Potentials by an Antidepressant

12 normal healthy controls will be treated with 50 mg sertraline once daily for three weeks. Early amplitudes of visually evoked potentials will be examined at day 0, 10 and 21 and statistically compared. This study aims to examine a putative modulation of synaptic transmission and plasticity by an antidepressant and is part of a series of studies in healthy individuals and depressed patients.


Eligibility Criteria:
Inclusion Criteria:

* healthy individuals 18-65 years

Exclusion Criteria:

* history of affective oder other psyhiatric disorder
* severe medical condition
* pregnancy or ineffective contraception
* active illicit drug use